drugset / Trial / NCT01579279
A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic neuropathic pain. People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
Timeline
- Start
- 2012-04
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-652 | Unknown | 6 mg | — |
| Subject | ABT-652 | Unknown | 12 mg | — |
| Subject | ABT-652 | Unknown | 18 mg | — |
| Comparator | Duloxetine | Small molecule | — | — |